BioStata   Report issue

For profit Phase 2 Phase 3
Founded: Birkerød Denmark (1982)

Organization Overview

First Clinical Trial
2013
NCT01895205
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

iron isomaltoside (7 trials)

red blood cells (1 trial)

sucroferric oxyhydroxide (velphoro) (1 trial)

Drugs in Phase 2 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Deficiency Diseases (Phase 3)

Hemorrhage (Phase 3)

Postpartum Hemorrhage (Phase 3)

Psychomotor Agitation (Phase 2)

Restless Legs Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4